The team began by purifying GEP from dried Gastrodia elata collected in Xiaocaoba, Zhaotong City, using hot-water extraction followed by ethanol precipitation and deproteinization. Chemical characterization revealed a remarkably pure preparation: total sugar content reached 90.04 percent, while protein contamination was a mere 1.72 percent. High-performance gel permeation chromatography showed a single symmetric peak corresponding to an average molecular weight of about 314 kilodaltons, placing GEP firmly in the category of large macromolecular polysaccharides. Monosaccharide analysis identified glucose as the dominant building block, and Fourier transform infrared spectroscopy confirmed a classic α-glucopyranose architecture, with absorption peaks marking hydroxyl stretching, pyranose ring vibrations, and α-glycosidic bonds. These structural details matter because the size, composition, and linkage chemistry of a polysaccharide determine how gut bacteria ferment it and which microbial species thrive on it.

With the molecule characterized, the researchers turned to cellular models. They exposed BV2 microglial cells, the resident immune cells of the brain, to d-galactose, a sugar widely used to induce senescence in laboratory settings. After 24 hours, cell viability fell in a concentration-dependent manner, with 200 millimolar d-galactose cutting viability roughly in half. Staining for senescence-associated β-galactosidase, a standard molecular marker of aged cells, confirmed that the treatment had pushed the microglia into a senescent state. When the team co-treated the cells with graded doses of GEP, the polysaccharide reversed the viability loss and significantly reduced the fraction of senescent cells, with 40 micrograms per milliliter showing the strongest effect. Senescent microglia are considered a central driving force of brain aging because they fuel chronic neuroinflammation, so rescuing them from senescence is a meaningful therapeutic signal.

The next test was one of the most demanding in aging biology: lifespan extension in Caenorhabditis elegans. Synchronized nematodes were raised from the first larval stage on plates containing 0.25, 0.5, or 1.0 milligram per milliliter of GEP. Because many plant polysaccharides have antibacterial properties that could indirectly extend lifespan by restricting the worms’ bacterial food supply and triggering caloric restriction, the researchers used heat-inactivated Escherichia coli OP50 as a uniform food source across all groups, carefully excluding this confounding pathway. Survival was tracked daily, and Kaplan–Meier analysis showed that GEP significantly prolonged average lifespan, with the 0.5 milligram per milliliter dose performing best. The result established that the anti-senescence activity seen in cells translates into a whole-organism longevity benefit.

The centerpiece of the study, however, was a natural aging model in mice, which avoids the artificialities of chemically induced senescence. Seventy-five eighteen-month-old male C57BL/6J mice were divided into groups receiving vehicle, vitamin E as a positive control, or GEP at 100, 200, or 400 milligrams per kilogram by daily oral gavage for two months, alongside fifteen two-month-old young controls. After the treatment period, the animals faced a battery of behavioral challenges. In the Morris water maze, aging mice took significantly longer to locate a hidden platform during five days of navigation training, and in the probe trial they spent less time in the target quadrant and crossed the platform position fewer times. Medium- and high-dose GEP shortened escape latencies and restored probe performance, with the medium dose showing the most pronounced improvement. Nest building, a sensitive index of social and autonomous function, was similarly depressed in aged mice and restored by GEP. Grip strength and wire-mesh climbing endurance, both of which decline with age, also rebounded under GEP treatment.

Histology explained the behavioral rescue. Hematoxylin–eosin staining of the hippocampus revealed that aging had disordered the neurons, shrunken their nuclei, and increased the number of damaged cells, while GEP preserved normal neuronal morphology and arrangement. Immunohistochemistry showed that GEP upregulated brain-derived neurotrophic factor, or BDNF, a core factor for neuronal survival and synaptic plasticity whose expression drops in the aging hippocampus. Notably, the medium dose of 200 milligrams per kilogram outperformed both the high dose and vitamin E across behavioral, histological, and molecular endpoints, producing a consistent inverted U-shaped dose–response curve. The authors suggest that excessively high polysaccharide concentrations may mildly overstimulate innate immune signaling in the gut, partially counteracting the compound’s own antioxidant and anti-inflammatory benefits, though they acknowledge this hypothesis requires further validation.

The molecular analysis traced the benefits to two canonical signaling axes. In serum and brain tissue, aging mice showed elevated malondialdehyde, a lipid peroxidation marker of oxidative damage, alongside reduced activities of the antioxidant enzymes superoxide dismutase and catalase. GEP reversed all three indicators. Western blotting revealed the mechanism: aging increased the expression of Keap1, the cytosolic protein that tags the transcription factor Nrf2 for degradation, and suppressed the downstream antioxidant enzymes HO-1 and NQO1. GEP downregulated Keap1 and restored HO-1 and NQO1, reactivating the Nrf2/Keap1 antioxidant defense system. Total Nrf2 protein levels were unchanged across groups, which the authors note is consistent with the pathway’s canonical regulation, since Nrf2 activation depends on nuclear translocation rather than increased total abundance, and the robust rise in downstream enzymes provides functional proof of pathway activation.

On the inflammatory side, the researchers measured the cytokines IL-1β, IL-6, and TNF-α by enzyme-linked immunosorbent assay and found them significantly elevated in both serum and brain of aged mice, the systemic fingerprint of inflammaging. The TLR4/NF-κB pathway, which drives this inflammatory transcription program, was correspondingly overactive, with increased TLR4 expression and heightened phosphorylation of the NF-κB subunit P65. GEP treatment suppressed TLR4 and reduced P65 phosphorylation, cutting the release of pro-inflammatory cytokines and breaking the vicious cycle in which oxidative stress fuels inflammation and inflammation in turn generates more reactive oxygen species.

The gut microbiota data tied the whole story together. Sixteen S ribosomal RNA sequencing of fecal samples showed that aging significantly reduced α-diversity and shifted the overall microbial composition away from that of young mice, as confirmed by principal coordinate analysis. At the phylum level, aging increased Bacteroidota and Pseudomonadota while depleting Bacillota and Verrucomicrobiota; at the genus level, beneficial taxa such as Lactobacillus and Dubosiella fell sharply, Akkermansia declined modestly, and Blautia was abnormally enriched. GEP reversed each of these shifts, restoring diversity and pushing the microbial profile of aged mice back toward the young control pattern. Critically, immunofluorescence of colon tissue showed that aging depleted the tight junction proteins ZO-1 and Occludin, the molecular seals of the intestinal barrier, and GEP restored both, outperforming vitamin E. This barrier repair is central to the proposed mechanism: a leaky aging gut allows lipopolysaccharide to enter the bloodstream, cross the blood–brain barrier, and activate TLR4/NF-κB signaling in microglia, driving neuroinflammation and cognitive decline. By resealing the gut, GEP may block this endotoxin traffic at its source.

The authors are candid about the implications and the limitations. Because GEP’s 314-kilodalton size prevents it from crossing an intact blood–brain barrier, its primary target must be the gastrointestinal tract, with brain protection arriving indirectly through the gut–brain axis, possibly via short-chain fatty acids and other microbial metabolites that the study did not measure directly. The work also lacked glycosidic linkage analysis by methylation and two-dimensional NMR, which would clarify how the polysaccharide’s structure governs its fermentability by taxa like Akkermansia, and the findings rest on mice aged twenty months, leaving older cohorts untested. Even so, the convergence of evidence across worms, cells, and mice, spanning behavior, histology, redox biochemistry, inflammatory signaling, microbiome sequencing, and barrier integrity, makes a compelling case that a single natural polysaccharide can coordinate oxidative stress, inflammation, and gut ecology simultaneously. As populations worldwide age and the search for safe multi-target interventions intensifies, GEP’s demonstration that a large, indigestible sugar molecule can protect the brain by way of the gut may prove to be the study’s most enduring insight.

Subject of Research: Anti-aging effects of Gastrodia elata polysaccharide via oxidative stress, inflammation, and gut microbiota modulation

Article Title: Gastrodia elata Polysaccharide Attenuates Aging by Modulating Oxidative Stress, Inflammation, and Gut Microbiota

Article References: Shi, H., Yang, S., Chen, Y., Shaog, B., Gong, R., & Li, Z. (2026). Gastrodia elata Polysaccharide Attenuates Aging by Modulating Oxidative Stress, Inflammation, and Gut Microbiota. Food Science & Nutrition, 14(10), Article e72413. https://doi.org/10.1002/fsn3.72413

Image Credits: AI Generated

DOI: 10.1002/fsn3.72413

Keywords: Gastrodia elata, polysaccharide, aging, oxidative stress, Nrf2/Keap1, TLR4/NF-κB, gut microbiota, intestinal barrier, BDNF, Caenorhabditis elegans, inflammaging, gut-brain axis

Erythroleukemia is an uncommon subtype of acute myeloid leukemia in which malignant transformation occurs in cells committed to becoming red blood cells. Clinically, the disease is notorious not only for its aggressive course but also for the way it cripples the immune system. T cell dysfunction sits at the heart of that immunosuppression, leaving patients with weakened defenses against both the malignancy itself and opportunistic infections. The spleen, a key reservoir of immune cells, often becomes enlarged, or splenomegalic, as malignant cells infiltrate the organ and distort its architecture. Restoring normal immune activity in this compromised environment has long been a challenge, and the new study suggests that a molecule better known for protecting the brain may help do exactly that.

Gastrodin has a long pharmacological pedigree. Derived from Gastrodia elata, a plant used for centuries in Chinese medicine to treat headaches, dizziness and neurological complaints, the compound has been shown in modern research to possess neuroprotective, anti-inflammatory and immunomodulatory activities. Recent reviews have catalogued its effects across the central nervous system and beyond, and earlier preclinical work even found that gastrodin could enhance the migration of engineered chimeric antigen receptor T cells toward brain tumors. What had never been tested, however, was whether the molecule could meaningfully improve immune function in the setting of leukemia. The Guizhou team set out to answer that question using a well-established mouse model of erythroleukemia.

The results were striking. Mice treated with gastrodin showed a significant alleviation of splenomegaly, indicating that the drug eased the malignant expansion that distorts the spleen in this disease. Treatment also inhibited the overall malignant progression of erythroleukemia in the animals. Beyond these direct anti-leukemic effects, the researchers documented a measurable revival of immune competence: splenic T cells from gastrodin-treated mice displayed markedly enhanced proliferative capacity, meaning they could divide and expand far more vigorously than T cells from untreated leukemic animals. The compound also promoted the secretion of immune-related cytokines, the chemical messengers that coordinate antitumor responses and orchestrate communication between immune cell populations.

To understand how a simple plant-derived molecule could accomplish all this, the investigators turned their attention to the T cell receptor, or TCR, signaling pathway, the molecular circuit that translates recognition of a foreign antigen into T cell activation. When a T cell’s receptor engages its target, a cascade of intracellular events unfolds: the kinase LCK initiates the signal, ZAP-70 amplifies it, ITK and PKC propagate it downstream, and the IKK complex and the transcription factor NFκB carry the message into the nucleus, where genes governing proliferation, cytokine production and cell survival are switched on. In immunosuppressed leukemic hosts, this cascade is blunted, leaving T cells sluggish and unresponsive.

Gastrodin, the study found, reversed that blunting. The compound upregulated the expression of the key molecules in the TCR signaling pathway, including LCK, ZAP-70, ITK, PKC, IKK and NFκB, at both the messenger RNA level, measured by quantitative real-time polymerase chain reaction, and at the level of protein phosphorylation, detected by western blot analysis. Phosphorylation is the molecular switch that activates many of these signaling proteins, so the finding that gastrodin boosted phosphorylated forms of the pathway components indicates that the drug did not merely increase the abundance of the machinery but also energized its function. Immunohistochemistry was used to corroborate these changes within tissue, giving the team a multi-layered picture of pathway reactivation in the spleen.

The mechanistic story did not end there. Through integrated bioinformatics analysis, molecular docking simulations and cellular thermal shift assays, the researchers identified a surprising potential interaction partner: Fli-1, a transcription factor with a famous history in erythroleukemia research. Fli-1, a member of the ets gene family, was originally discovered as a common proviral integration site in erythroleukemia cells induced by the Friend murine leukemia virus, and decades of work have established its role in hematopoiesis and malignant transformation. The cellular thermal shift assay, a technique that detects whether a small molecule physically binds to and stabilizes a protein inside cells, indicated that gastrodin exhibits a moderate interaction with Fli-1 in erythroleukemia. The authors are careful to note that this physical interaction is only a first clue: the functional contribution of Fli-1 binding to the compound’s immune-enhancing effects remains to be further explored.

That caveat matters, but the Fli-1 connection is intriguing for reasons that extend beyond this single study. Prior research has shown that Fli-1 influences T cell behavior, including the regulation of thymocyte development and the enhancement of TCR signal strength during gamma-delta T cell commitment, and that reducing FLI1 levels in lupus-prone mice alters T cell function through metabolic changes. Other recent work has implicated FLI1 in tumor immune evasion, showing that the transcription factor promotes interferon-gamma-induced kynurenine production that impairs antitumor immunity. A natural molecule that physically engages Fli-1 while simultaneously reviving TCR signaling therefore opens several testable hypotheses about how the compound might be rewiring the leukemic immune microenvironment, whether through direct transcriptional effects or through the downstream amplification of T cell activation circuits.

The study’s methodology reflects a modern, multi-pronged approach to natural product pharmacology. Animal experiments, approved by the Animal Ethics Committee of Guizhou Medical University, established the therapeutic effects in vivo. Molecular biology techniques, including qRT-PCR, western blotting and immunohistochemistry, mapped the signaling changes. Bioinformatics and molecular docking then narrowed the field of candidate protein targets, and the cellular thermal shift assay provided biophysical evidence of a drug-protein interaction. The work was supported by the National Natural Science Foundation of China and several Guizhou provincial funding programs, and the authors report no competing interests. The team included researchers from Guizhou Medical University’s State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, the Natural Products Research Center of Guizhou Province, Baiyun Affiliated Hospital of Guizhou Medical University and Guizhou Wansheng Pharmaceutical.

For the field, the implications are twofold. First, the findings position gastrodin as a promising immunotherapeutic candidate for erythroleukemia, a disease in which treatment options remain limited and immune restoration is an unmet need. Because gastrodin has a long history of human use in traditional medicine and a favorable safety profile in prior pharmacological studies, the path from a mouse model toward translational exploration may be shorter than for entirely novel synthetic compounds. Second, the study adds to a growing body of evidence that natural small molecules can modulate core immune signaling pathways in cancer, complementing approaches such as immune checkpoint inhibitors and adoptive T cell therapies that dominate current immunotherapy. Whether gastrodin can deliver comparable benefits in human patients, at what dose, and with what long-term consequences are questions that will require further preclinical development and, eventually, clinical testing. The Fli-1 interaction, in particular, awaits functional validation. But as a first demonstration that a centuries-old herbal compound can switch T cell receptor signaling back on in a leukemic spleen, the study offers a compelling proof of concept that the boundary between traditional pharmacology and modern cancer immunotherapy is thinner than many might assume.

Subject of Research: The immunomodulatory effects of gastrodin on splenic T-cell immunity in erythroleukemia through regulation of the T-cell receptor signaling pathway.

Article Title: Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway

Article References: Cheng, S., Xu, Y., Wang, J., Yu, J., Hu, L., Liu, J., & Luo, H. (2026). Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway. Medical Oncology, 43(10), Article 291. https://doi.org/10.1007/s12032-026-03388-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03388-2

Keywords: gastrodin, erythroleukemia, T-cell receptor signaling, Fli-1, spleen immune function, Gastrodia elata, immunotherapy, leukemia, NF-kB, cytokines, molecular docking, natural products